JP6764866B2 - Ca2+放出活性化Ca2+(CRAC)チャネルのモジュレーターおよびその薬学的使用 - Google Patents
Ca2+放出活性化Ca2+(CRAC)チャネルのモジュレーターおよびその薬学的使用 Download PDFInfo
- Publication number
- JP6764866B2 JP6764866B2 JP2017533635A JP2017533635A JP6764866B2 JP 6764866 B2 JP6764866 B2 JP 6764866B2 JP 2017533635 A JP2017533635 A JP 2017533635A JP 2017533635 A JP2017533635 A JP 2017533635A JP 6764866 B2 JP6764866 B2 JP 6764866B2
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- compound
- pharmaceutically acceptable
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 claims description 235
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 167
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 117
- 201000010099 disease Diseases 0.000 claims description 114
- 229910052799 carbon Inorganic materials 0.000 claims description 74
- 150000003839 salts Chemical class 0.000 claims description 69
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 64
- 208000035475 disorder Diseases 0.000 claims description 53
- -1 C 1- C 6 cycloalkyl Chemical group 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 229910052801 chlorine Inorganic materials 0.000 claims description 37
- 239000012453 solvate Substances 0.000 claims description 36
- 229910052731 fluorine Inorganic materials 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 30
- 229910052794 bromium Inorganic materials 0.000 claims description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 26
- 206010025135 lupus erythematosus Diseases 0.000 claims description 25
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 21
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 17
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 16
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 15
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
- 201000001981 dermatomyositis Diseases 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 210000004556 brain Anatomy 0.000 claims description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 206010052779 Transplant rejections Diseases 0.000 claims description 9
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 230000001363 autoimmune Effects 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 7
- 201000010105 allergic rhinitis Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000023328 Basedow disease Diseases 0.000 claims description 5
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 5
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 5
- 208000006386 Bone Resorption Diseases 0.000 claims description 5
- 208000020084 Bone disease Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 230000024279 bone resorption Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- 206010010996 Corneal degeneration Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 208000010334 End Stage Liver Disease Diseases 0.000 claims description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 4
- 206010024229 Leprosy Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000032159 Vaginal inflammation Diseases 0.000 claims description 4
- 201000008100 Vaginitis Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 208000011444 chronic liver failure Diseases 0.000 claims description 4
- 206010014801 endophthalmitis Diseases 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 208000013256 infectious meningitis Diseases 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 230000036473 myasthenia Effects 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 208000009928 nephrosis Diseases 0.000 claims description 4
- 231100001027 nephrosis Toxicity 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 201000001245 periodontitis Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 206010043778 thyroiditis Diseases 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000005374 Poisoning Diseases 0.000 claims description 3
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 231100000572 poisoning Toxicity 0.000 claims description 3
- 230000000607 poisoning effect Effects 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 206010043207 temporal arteritis Diseases 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000005446 Lupus vulgaris Diseases 0.000 claims description 2
- 208000021908 Myocardial disease Diseases 0.000 claims description 2
- 206010058461 Orchitis noninfective Diseases 0.000 claims description 2
- 241000519995 Stachys sylvatica Species 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 238000011316 allogeneic transplantation Methods 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 239000011575 calcium Substances 0.000 description 99
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 90
- 229910052736 halogen Inorganic materials 0.000 description 67
- 150000002367 halogens Chemical class 0.000 description 67
- 239000003814 drug Substances 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 46
- 125000000217 alkyl group Chemical group 0.000 description 40
- 241000124008 Mammalia Species 0.000 description 37
- 239000000460 chlorine Substances 0.000 description 34
- 150000001721 carbon Chemical group 0.000 description 33
- 108091006146 Channels Proteins 0.000 description 32
- 229940079593 drug Drugs 0.000 description 31
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 29
- 229940125904 compound 1 Drugs 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 229940125782 compound 2 Drugs 0.000 description 27
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 26
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 25
- 229940002612 prodrug Drugs 0.000 description 24
- 239000000651 prodrug Substances 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 230000004941 influx Effects 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 102000020167 Calcium release-activated calcium channel Human genes 0.000 description 18
- 108091022898 Calcium release-activated calcium channel Proteins 0.000 description 18
- 230000002025 microglial effect Effects 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 230000004913 activation Effects 0.000 description 15
- 125000004093 cyano group Chemical group *C#N 0.000 description 15
- 101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- 125000000623 heterocyclic group Chemical group 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 125000004404 heteroalkyl group Chemical group 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 125000004430 oxygen atom Chemical group O* 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 101150060735 orai1 gene Proteins 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 229910001868 water Inorganic materials 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000003959 neuroinflammation Effects 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000024777 Prion disease Diseases 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 201000002491 encephalomyelitis Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003567 signal transduction assay Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 101100043696 Drosophila melanogaster Stim gene Proteins 0.000 description 3
- 241000792859 Enema Species 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 101150066814 Orai3 gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102000004094 Stromal Interaction Molecule 1 Human genes 0.000 description 3
- 108090000532 Stromal Interaction Molecule 1 Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 229940095399 enema Drugs 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000023514 Barrett esophagus Diseases 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000483002 Euproctis similis Species 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101000643017 Homo sapiens Stromal interaction molecule 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010023774 Large cell lung cancer Diseases 0.000 description 2
- 241001424413 Lucia Species 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027926 Monoplegia Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 102000049666 ORAI1 Human genes 0.000 description 2
- 108700027851 ORAI1 Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102000005935 Stromal Interaction Molecule 2 Human genes 0.000 description 2
- 108010030731 Stromal Interaction Molecule 2 Proteins 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229940125400 channel inhibitor Drugs 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 239000001064 degrader Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000053977 human STIM1 Human genes 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000009546 lung large cell carcinoma Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000006241 metabolic reaction Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000004500 stellate cell Anatomy 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- AZZDPMNJQSOALT-UHFFFAOYSA-N 3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(1H-pyrrol-2-yl)propan-1-one Chemical compound C(C)(C)(C)C=1C=C(C=C(C=1O)C(C)(C)C)CCC(=O)C=1NC=CC=1 AZZDPMNJQSOALT-UHFFFAOYSA-N 0.000 description 1
- QCHFPZWKEOMATK-UHFFFAOYSA-N 3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(3,4,5-trichloro-1H-pyrrol-2-yl)propan-1-one Chemical compound C(C)(C)(C)C=1C=C(C=C(C=1O)C(C)(C)C)CCC(=O)C=1NC(=C(C=1Cl)Cl)Cl QCHFPZWKEOMATK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010051288 Central nervous system inflammation Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- YVECGMZCTULTIS-HSUXUTPPSA-N D-galactal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@H]1O YVECGMZCTULTIS-HSUXUTPPSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000041751 Orai family Human genes 0.000 description 1
- 108091074751 Orai family Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 125000005361 aryl sulfoxide group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- YINMBLWEHNCLFF-UHFFFAOYSA-N benzenesulfonic acid;benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 YINMBLWEHNCLFF-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- HABLENUWIZGESP-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O HABLENUWIZGESP-UHFFFAOYSA-N 0.000 description 1
- NXMUXTAGFPJGTQ-UHFFFAOYSA-N decanoic acid;octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCCCC(O)=O NXMUXTAGFPJGTQ-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- QJZOIPFECDFUMS-UHFFFAOYSA-N ethane-1,2-disulfonic acid;ethanesulfonic acid Chemical compound CCS(O)(=O)=O.OS(=O)(=O)CCS(O)(=O)=O QJZOIPFECDFUMS-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000006775 microglial inflammation Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000004292 pyrrolin-2-yl group Chemical group [H]C1([H])N=C(*)C([H])([H])C1([H])[H] 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本出願は、2015年1月13日に出願された米国出願第62/103,033号の利益を主張し、当該文献は参照により全体として本明細書に組み込まれる。
R1はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C3−C6シクロアルキル、C1−C6ヒドロキシアルキル、またはC1−C6ヘテロアルキルであり、
R2はC1−C6アルコキシまたはヒドロキシであり、
R3はC1−C6アルコキシまたはヒドロキシであり、あるいは、R2とR3は、それらが結合する炭素原子と一体となって、−C(=O)−、−C(=NR13)、−C(=N−OR13)−、または2つのO原子を含有する複素環を形成し、
R13はHまたはC1−C6アルキルであり、
R4は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり、
R5は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり、あるいは、R4とR5は、それらが結合する炭素原子と一体となって、置換または非置換のC3−C6シクロアルキル環、あるいは−O−、−NR12− および、−S−から選択された1つまたは2つのヘテロ原子を含む置換または非置換のC3−C6複素環を形成し、
R6は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり、
R7は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり、あるいは、R6とR7は、それらが結合する炭素原子と一体となって、置換または非置換のC3−C6シクロアルキル環、あるいは−O−、−NR12− および、−S−から選択された1つまたは2つのヘテロ原子を含む置換または非置換のC3−C6複素環を形成し、
R8は、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、または−NHC(=O)OR11であり、
R9は、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、または−NHC(=O)OR11であり、あるいは、
R10はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、または−NHC(=O)OR11であり、
R11はそれぞれ独立して、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、またはC3−C6シクロアルキルであり、
R12はそれぞれ独立して、H、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、またはC3−C6シクロアルキルであり、
nは0、1、2、または3であり、および、
mは0、1、2、または3である。
CRACチャネルはT細胞を含む多くの細胞の適切な機能にとって必要不可欠である。CRACチャネル開口は、Ca2+イオンがその濃度勾配に沿って細胞の細胞質へ流れるのに好ましい電気化学的環境を整える。CRACチャネルを通るCa2+の流入は開口分泌を引き起こし、ミトコンドリアの代謝を刺激し、遺伝子発現を活性化し、細胞の成長と増殖を促し、インテグリンを活性化し、サイトカイン産生を可能にし、ヒスタミン放出を促す。CRACチャネル活性化は、T細胞受容体、B細胞受容体、およびGタンパク質共役受容体を含む、原形質膜上の受容体の会合後に生じる。Ca2+は重要な細胞内の二次メッセンジャーとして作用し、多数のCa2+依存性のシグナル伝達と、活性化B細胞(NF−κB)の核因子κ軽鎖エンハンサーと活性化T細胞(NFAT)の核因子を含む転写因子タンパク質の活性化を可能にする。
いくつかの例では、CRAC経路機能の阻害は、炎症誘発性の免疫機能を防ぐ、および/または抗炎症反応を増強するのに効果的である。いくつかの例では、Orai1のCa2+シグナル伝達カスケードを介して活性化される細胞は、様々なケモカインとサイトカインを産生する。ケモカインとサイトカインは、産生の部位で、および身体全体で広範囲の生理的なプロセスを媒介する。あるケモカインとサイトカインは、ホメオスタシス中に正常な細胞の機能を媒介し、別のものは感染中または組織損傷の後に保護を与え、別のものは多くの病状の免疫病原性を媒介する。
本明細書に記載される化合物は、その薬学的に許容可能な塩、プロドラッグ、活性代謝物、および薬学的に許容可能な溶媒和物を含んでおり、CRACチャネル阻害剤である。
R1はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C3−C6シクロアルキル、C1−C6ヒドロキシアルキル、またはC1−C6ヘテロアルキルであり;
R2はC1−C6アルコキシまたはヒドロキシであり;
R3はC1−C6アルコキシまたはヒドロキシであり;
または、R2とR3は、それらが結合される炭素原子と一体となって、−C(=O)−、−C(=NR13)−、−C(=N−OR13)−、または2つのO原子を含む複素環を形成し;
R13はHまたはC1−C6アルキルであり;
R4は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
R5は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
または、R4とR5は、それらが結合される炭素原子と一体となって、置換または非置換のC3−C6シクロアルキル環、またはO−、−NR12−、およびS−から選択される1または2のヘテロ原子を含む置換または非置換のC3−C6複素環を形成し;
R6は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
R7は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
または、R6とR7は、それらが結合される炭素原子と一体となって、置換または非置換のC3−C6シクロアルキル環、またはO−、−NR12−、およびS−から選択される1または2のヘテロ原子を含む置換または非置換のC3−C6複素環を形成し;
R8は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、またはNHC(=O)OR11であり;
R9は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、またはNHC(=O)OR11であり;または
R10はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、またはNHC(=O)OR11であり;
R11はそれぞれ独立して、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、またはC3−C6シクロアルキルであり;
R12はそれぞれ独立して、H、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、またはC3−C6シクロアルキルであり;
nは0、1、2、または3であり;および
mは、0、1、2、または3である。
R1はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C3−C6シクロアルキル、C1−C6ヒドロキシアルキル、またはC1−C6ヘテロアルキルであり;
R2はC1−C6アルコキシまたはヒドロキシであり;
R3はC1−C6アルコキシまたはヒドロキシであり;
または、R2とR3は、それらが結合される炭素原子と一体となって、−C(=O)−、−C(=NR13)−、−C(=N−OR13)−、または2つのO原子を含む複素環を形成し;
R13はHまたはC1−C6アルキルであり;
R4は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
R5は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
または、R4とR5は、それらが結合される炭素原子と一体となって、置換または非置換のC3−C6シクロアルキル環、またはO−、−NR12−、およびS−から選択される1または2のヘテロ原子を含む置換または非置換のC3−C6複素環を形成し;
R6は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
R7は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
または、R6とR7は、それらが結合される炭素原子と一体となって、置換または非置換のC3−C6シクロアルキル環、またはO−、−NR12−、およびS−から選択される1または2のヘテロ原子を含む置換または非置換のC3−C6複素環を形成し;
R8は、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、またはNHC(=O)OR11であり;
R9は、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、またはNHC(=O)OR11であり;または
R10はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、C1−C6シクロアルキル、C1−C6ヒドロキシアルキル、C1−C6ヘテロアルキル、−CN、−NO2、−OH、−OR11、−SR11、−S(=O)R11、−S(=O)2R11、−S(=O)2N(R12)2、−NR12S(=O)2R11、−C(=O)R11、−OC(=O)R11、−CO2R12、−OCO2R11、−N(R12)2、−C(=O)N(R12)2、−OC(=O)N(R12)2、−NHC(=O)R11、またはNHC(=O)OR11であり;
R11はそれぞれ独立して、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、またはC3−C6シクロアルキルであり;
R12はそれぞれ独立して、H、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6ジュウテロアルキル、またはC3−C6シクロアルキルであり;
nは0、1、2、または3であり;および
mは、0、1、2、または3である。
R1はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C3−C6シクロアルキルであり;
R2とR3は、それらが結合される炭素原子と一体となって、−C(=O)−、−C(=NR13)−、−C(=N−OR13)−、または、2つのO原子を含む複素環を形成し;
R13はHまたはC1−C6アルキルであり;
R4は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
R5は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;
R6は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルであり;および
R7は、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、またはC1−C6ジュウテロアルキルである。
R1はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C3−C6シクロアルキルであり;
R2とR3は、それらが結合される炭素原子と一体となって、−C(=O)−を形成し;
R4は、H、ハロゲン、メチル、エチル、シクロプロピル、またはシクロブチルであり;
R5は、H、ハロゲン、メチル、エチル、シクロプロピル、またはシクロブチルであり;
R6は、H、ハロゲン、メチル、エチル、シクロプロピル、またはシクロブチルであり;および
R7は、H、ハロゲン、メチル、エチル、シクロプロピル、またはシクロブチルである。
R1はそれぞれ独立して、H、ハロゲン、C1−C6アルキル、C1−C6フルオロアルキル、C3−C6シクロアルキルであり;
R2とR3は、それらが結合される炭素原子と一体となって、−C(=O)−を形成し;
R4はH、F、Cl、またはメチルであり;
R5はH、F、Cl、またはメチルであり;
R6はH、F、Cl、またはメチルであり;および
R7は、H、F、Cl、またはメチルである。
本明細書に記載される反応に使用される化合物は、当業者に既知の有機合成技術に従って作られ、商業上利用可能な化学物質からおよび/または化学文献に記載される化合物から出発する。「商業上利用可能な化学物質」は、Acros Organics(Pittsburgh,PA)、Aldrich Chemical(Milwaukee,WI,Sigma ChemicalとFlukaを含む)、Apin Chemicals Ltd.(Milton Park,UK)、Avocado Research(Lancashire,U.K.)、BDH Inc.(Toronto,Canada)、Bionet(Cornwall,U.K.)、Chemservice Inc.(West Chester,PA)、Crescent Chemical Co.(Hauppauge,NY)、Eastman Organic Chemicals、Eastman Kodak Company(Rochester,NY)、Fisher Scientific Co.(Pittsburgh,PA)、Fisons Chemicals(Leicestershire,UK)、Frontier Scientific(Logan,UT)、ICN Biomedicals,Inc.(Costa Mesa,CA)、Key Organics(Cornwall,U.K.)、Lancaster Synthesis(Windham,NH)、Maybridge Chemical Co.Ltd.(Cornwall,U.K.)、Parish Chemical Co.(Orem,UT)、Pfaltz & Bauer,Inc.(Waterbury,CN)、Polyorganix(Houston,TX)、Pierce Chemical Co.(Rockford,IL)、Riedel de Haen AG(Hanover,Germany)、Spectrum Quality Product,Inc.(New Brunswick,NJ)、TCI America(Portland,OR)、Trans World Chemicals,Inc.(Rockville,MD)、およびWako Chemicals USA,Inc.(Richmond,VA)を含む、通常の商用供給源から得られる。
他に明記のない限り、本出願で使用される以下の用語は、以下に与えられる定義を有する。用語「含む(including)」に加えて、「含む(include)」、「含む(includes)」、および「含んだ(included)」などの他の形態の使用は、限定しない。
例えば、「1乃至10の炭素原子」は、アルキル基が、1つの炭素原子、2つの炭素原子、3つの炭素原子などから、最大10の炭素原子までの炭素原子から成ることを意味するが、本定義はさらに、数の範囲が指定されていない用語「アルキル」の出現も包含する。
いくつかの実施形態では、アルキルは、C1−C6アルキルである。一態様では、アルキルは、メチル、エチル、プロピル、イソ−プロピル、n−ブチル、イソ−ブチル、sec−ブチル、またはt−ブチルである。典型的なアルキル基は、まったく限定されないが、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、第三級ブチル、ペンチル、ネオペンチル、またはヘキシルを含む。
アルキニル基の限定しない例は、−C≡CH、−C≡CCH3 −C≡CCH2CH3、−CH2C≡CHを含む。
−S(=O)2NH(C1−C4アルキル)、−S(=O)2N(C1−C4アルキル)2、C1−C4アルキル、C3−C6シクロアルキル、C1−C4フルオロアルキル、C1−C4ヘテロアルキル、C1−C4アルコキシ、C1−C4フルオロアルコキシ、−SC1−C4アルキル、−S(=O)C1−C4アルキル、および−S(=O)2C1−C4アルキルから独立して選択される。いくつかの実施形態では、随意の置換基は、ハロゲン、−CN、−NH2、−OH、−NH(CH3)、−N(CH3)2、−CH3、−CH2CH3、−CF3、−OCH3、および−OCF3から独立して選択される。いくつかの実施形態では、置換された基は、前述の基の1つまたは2つと置換される。いくつかの実施形態では、脂肪族炭素原子(非環式または環式)上の随意の置換基は、オキソ(=O)を含む。
いくつかの実施形態では、本明細書に記載される化合物は、医薬組成物へと製剤される。医薬組成物は、薬学的に使用される調剤への活性化合物の処理を促進する1つ以上の薬学的に許容可能な不活性成分を使用して、従来の方法で製剤される。適切な製剤は、選択される投与の経路に依存する。本明細書に記載される医薬組成物の概要は、例えば、Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980;およびPharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed.(Lippincott Williams & Wilkins1999)で見られ、これらは、そのような開示のための引用によって本明細書に組み込まれる。
一実施形態では、本明細書に記載される化合物、またはその薬学的に許容可能な塩は、CRACチャネル活性の阻害または減少から恩恵を得ることになる哺乳動物における疾患または疾病の処置のための薬剤の調製に使用される。そのような処置を必要としている哺乳動物において本明細書に記載される疾患または疾病のいずれかを処置するための方法は、本明細書に記載される少なくとも1つの化合物、またはその薬学的に許容可能な塩、活性代謝物質、プロドラッグ、または薬学的に許容可能な溶媒和物を含む、医薬組成物を、治療上有効な量で、前記哺乳動物に投与する工程を含む。
いくつかの実施形態では、処置に必要な期間は様々であり、処置期間は、各被験体の具体的な必要性に合わせて調節される。例えば、具体的な実施形態では、本明細書に記載される化合物または該化合物を含有している製剤は、少なくとも2週間、約1か月から約5年間投与される。
化合物1を、ピロールの標準的なフリーデル・クラフツアシル化によって1工程で調製した。(模式図1を参照)質量スペクトルを、エレクトロスプレーイオン化を使用して、質量分析計上に記録した。化合物1:ES+m/z 328.2[M+H]+, calcd.for C21H29NO2 正確な質量:327.0。
化合物2を、塩素分子での塩素化と、その後のクロマトグラフィー精製によって、化合物1から調製した。質量スペクトルを、エレクトロスプレーイオン化を使用して、質量分析計上に記録した。化合物2:ES+m/z 430.3[M+H]+, calcd.for C21H29Cl3NO2 正確な質量:429.0。
注入(皮下、静脈内)による投与に適した非経口医薬組成物を調製するために、本明細書に記載される1−100mgの化合物の水溶性塩、あるいはその薬学的に許容可能な塩または溶媒和物を、滅菌水中に溶解し、その後、0.9%の無菌食塩水10mLと混合する。適切な緩衝液を、随意の酸または塩基とともに加え、pHを調節する。混合物を、注入による投与に適した単位剤形に組み込む。
経口送達用の医薬組成物を調製するために、本明細書に記載される十分な量の化合物、またはその薬学的に許容可能な塩を、(随意の可溶化剤、随意の緩衝液、および矯味賦形剤(taste masking excipients)とともに)水に加え、20mg/mLの溶液を提供する。
錠剤を、本明細書に記載される20−50重量%の化合物、またはその薬学的に許容可能な塩、20−50重量%の微結晶性セルロース、1−10重量%の低置換のヒドロキシプロピルセルロース、および1−10重量%のステアリン酸マグネシウムまたは他の適切な賦形剤を混合することによって調製する。錠剤を直接圧縮によって調製する。圧縮錠剤の全重量を、100−500mgで維持する。
経口送達用の医薬組成物を調製するために、本明細書に記載される10−500mgの化合物、またはその薬学的に許容可能な塩を、デンプンまたは他の適切な粉末ブレンドと混合する。混合物を、経口投与に適した、硬ゼラチンカプセルなどの経口剤形に組み込む。
式(I)の化合物を、カルシウム指示染料(Fluo−4)でヒトJurkat T細胞を処置することによってCa2+シグナル伝達の阻害のためにスクリーニングし、Ca2+流入の検出を可能にする。その後、Jurkat細胞を、式(I)の化合物で培養し、植物性赤血球凝集素PHA−Pで活性化し、Ca2+流入を誘発する。活性化の直後、フローサイトメーター上で蛍光を判定する。
化合物2を、化合物2の存在下で細胞内のCa2+応答を検査することによってCa2+シグナル伝達の阻害のためにスクリーニングした(図2)。最初に、ヒト急性T細胞リンパ芽球性白血病の不死化株である、ヒトJurkat T細胞に、2μMのCa2+指示染料(Fluo−4)を充填し、Ca2+流入の検出を可能にした。その後、Jurkat細胞を、化合物2で培養し、植物性赤血球凝集素PHA−Pで活性化し、Ca2+流入を誘発した。活性化の直後、フローサイトメーターを使用してJurkat蛍光を測定することによって、Ca2+流入を判定した。未刺激対照と比較した平均のFluo−4蛍光強度の2.9倍の増加とともに、最大のCa2+流入が生じた。未刺激対照と比較した0.35倍の増加とともに、Ca2+流入の最大の阻害が生じた。化合物2は、3.78μMのIC50を有してCa2+流入を強力に阻害した。
化合物1の存在下で細胞内のCa2+応答を検査することによって、化合物1をCa2+シグナル伝達の阻害のためにスクリーニングした(図8)。最初に、ヒト胚腎臓293細胞を、組み換えヒトOrai1および組み換えヒトSTIM1を用いてリポフェクタミンによってトランスフェクトした。トランスフェクトされた細胞にうまくラベル付けするために、組み換えヒトOrai1に、増強された緑色蛍光タンパク質を遺伝的にタグ付けした。細胞を、カバーガラス上に蒔き、それに2μMのCa2+指示染料(Fura−2)を充填し、細胞内のCa2+濃縮の検出を可能にした。蛍光励起を340ナノメートルおよび380ナノメートルで交替させることによって、細胞性蛍光を判定した。単細胞蛍光を溶液交換中に測定し、これは、化合物1が、CRACチャネルでトランスフェクトしたヒト胚細胞においてストア感受性Ca2+(SOC)チャネルを調節することを示唆している。
式(I)の化合物を、カルシウム指示染料(Fluo−4)でヒトJurkat T細胞を処置することによってCa2+シグナル伝達の阻害のためにスクリーニングし、Ca2+流入の検出を可能にする。その後、Jurkat細胞を、式(I)の化合物で培養し、タプシガルジンで活性化し、Ca2+流入を誘発する。活性化の直後、フローサイトメーター上で蛍光を判定する。
化合物2の存在下で細胞分裂を定量化することによって、化合物2を一次ヒトT細胞増殖の阻害のためにスクリーニングした(図3)。最初に、96ウェルのプレートを、摂氏4度で一晩、リン酸緩衝生理食塩水中で4μg/mLの抗CD3抗体(クローン:OKT3)でコーティングした。その後、一次ヒトT細胞を、抗体ベースのヒトT細胞富化プロトコルを使用して、健全な同意したドナーの末梢血から分離した。その後、ヒトT細胞を、1.75μMのカルボキシフルオレセイン・スクシンイミジルエステルで染色し、細胞増殖の検出を可能にした。その後、ヒトT細胞を、化合物2で培養し、固定化した抗CD3抗体および1μg/mLの可溶性抗CD28(クローン:CD28.2)抗体および0.2ng/mLの組み換えヒトIL−2で活性化し、NFATおよびNF−κB転写因子経路によって細胞増殖を誘発した。標準培養条件で72時間後、カルボキシフルオレセイン・スクシンイミジルエステルでの希釈のフローサイトメトリー解析によって、増殖をアッセイした。未刺激対照と比較した活性化指数の3.9倍の増加とともに、最大の増殖が生じた。未刺激対照と比較した0.91倍の増加とともに、増殖の最大の阻害が生じた。化合物2は、671nMのIC50を有して一次ヒトT細胞増殖を強力に阻害した。
ヒトJurkat T細胞およびヒトRamos B細胞の両方をcell−tracker dyeのカルボキシフルオレセイン・スクシンイミジルエステルCFSEで処置することによって、式(I)の化合物を、白血性の癌細胞増殖の阻害のためにスクリーニングし、細胞増殖の検出を可能にする。その後、癌細胞を5日間式(I)の化合物で培養する。培養期間後、フローサイトメーター上で蛍光を判定する。
化合物2の存在下で細胞死を定量化することによって、化合物2を癌細胞生存の阻害のためにスクリーニングした(図4)。ヒト急性T細胞リンパ芽球性白血病の不死化株である、ヒトJurkat T細胞(■)、ヒトバーキットリンパ腫の不死化株である、Ramos B細胞(●)、および健全な同意したドナーの末梢血から分離された、一次ヒトT細胞(▲)を、化合物2の存在下で培養し、細胞生存および細胞死に関して試験した。細胞を標準培養条件で培養し、一次ヒトT細胞も、4μg/mLの固定化した抗CD3(クローン:OKT3)抗体および1μg/mLの可溶性抗CD28(クローン:CD28.2)抗体および0.2ng/mLの組み換えヒトIL−2で活性化した。標準培養条件で一次ヒトT細胞に対して72時間後またはJurkat T細胞およびRamos B細胞に対して120時間後、細胞光散乱のフローサイトメトリー解析によって、細胞生存をアッセイした。前方および側方散乱の標準的なフローサイトメトリーのリンパ球分析ゲートを使用して、細胞生存のパーセンテージを、化合物2のない対照ウェルと比較した生存可能な細胞のパーセント減少として分析した。JurkatおよびRamosの細胞の生存度は、化合物2の存在下で低下し、健全なドナーからの一次ヒトT細胞の生存度は、化合物2の存在下で低下しなかった。
化合物2の存在下で細胞内のCa2+応答を検査することによって、化合物2をCa2+シグナル伝達の阻害のためにスクリーニングした(図5)。最初に、マウス小膠細胞の不死化株である、ネズミ小脳CRL−2540細胞に、2μMのCa2+指示染料(Fluo−4)を充填し、Ca2+流入の検出を可能にした。その後、CRL−2540細胞を化合物2で培養し、2μMのタプシガルジンで活性化し、Ca2+流入を誘発した。活性化の直後、フローサイトメーターを使用してCRL−2540蛍光を測定することによって、Ca2+流入を判定した。未刺激対照と比較した平均のFluo−4蛍光強度の0.52倍の増加とともに、最大のCa2+流入が生じた。未刺激対照と比較した0.19倍の増加とともに、Ca2+流入の最大の阻害が生じた。化合物2は、10.9μMのIC50を有してCa2+流入を強力に阻害した。
化合物1を、9週齢の雄のスプラーグドーリーラットに対して経口で(p.o.)(■)または静脈内(i.v.)(●)に投与した(図6)。生存した血液の採取のために、250−350μLの血液サンプルを、1研究プロトコル当たり提案された時間点で頚静脈(JUGVEIN)カニューレによって集め、記録した。血液を、投与前および化合物1の投与の15分、30分、1、2、4、12、24、および48時間後に採取した。血漿採取のために、血液をリチウムヘパリンチューブに集めた。較正標準および研究サンプルを、2用量の氷冷の内部標準液(Internal Standard Solution)(50ng/mLのデキストロメトルファン、5ng/mLのジフェンヒドラミンおよび125ng/mLのジクロフェナクを含有しているアセトニトリル)とともに40μLの各サンプルを沈澱させることによって、LC/MS/MS分析用に処理した。沈澱したサンプルを、30分間6100gで遠心分離にかけた。遠心分離後に、分割量の各上清を、オートサンプラープレートに移し、同量の0.2%のギ酸とともに水中に希釈した。処理した研究サンプルを、LC/MS/MSを使用して分析した。i.v.経路に関して、投与量は、10000μg/kg、Cmax 0.837μg/mL、Tmax 0.250hr、CL 14174mL/hr/kg、VSS 26904mL/kg、MRTinf 1.90hr、AUClast 0.694hr*μg/mL、AUC0‐inf 0.706hr*μg/mL、およびTerminal t1/2 2.64hであった。p.o.経路に関して、投与量は、10000μg/kg、Cmax 0.126μg/mL、Tmax 2hr、AUClast 0.679hr*μg/mL、AUC0‐inf 0.747hr*μg/mL、T1/2 3.27hr、およびバイオアベイラビリティ106%であった。動物の体重および臨床観察は、研究の全体にわたって正常に見えた。
化合物1を、極性化されたメイディン・ダービー・イヌ腎臓−多剤耐性タンパク質の1(MDCK−MDR1)の上皮細胞単層にわたる透過性に関して評価した。組織培養フラスコ中で成長したMDCK−MDR1細胞を、トリプシン処理し、培地中に懸濁し、懸濁液を、Millipore 96ウェルのCaco−2プレートのウェルに適用した(図7)。細胞を、成長させ、5日間分化させ、コンフルエンスを確認した。頂端側(Apical)から基底外側(Basolateral)(A−>B)の透過性に関して、化合物1を頂端(A)側に加え、透過の量を基底外(B)側で判定する;基底外側から頂端側(B−>A)の透過性に関して、化合物1をB側に加え、透過の量をA側で判定し、LC/MS/MSによって分析した。ラニチジンは「低透過性」対照であり;ワルファリンは「高透過性」対照であり;およびタリノロールは「排出対照(efflux control)」である。化合物1は、1.0*10−6cm s−1の平均のA−>B Papp a、1.6*10−6cm s−1の平均のB−>A Papp a、および1.6の排出率(efflux ratio)を有した。
活性化されたB細胞(NF−κB)−ルシフェラーゼレポーター遺伝子の核因子κ軽鎖エンハンサーで安定してトランスフェクトされたヒト急性単球性白血病THP1細胞を使用して、化合物1および2を炎症性の転写の阻害のためにスクリーニングした。THP1細胞を、ジメチルスルホキシド、30μMの化合物1または30μMの化合物2の存在下で、リポ多糖によって活性化した。細胞培養上清中のNF−κB誘発性のLuciaのレベルを、プレートリーダーのルシフェラーゼ検出試薬で評価した。*=p<0.05。***=p<0.001.(図9を参照)
化合物1を、C57/BL6マウスに皮下(s.c.)に投与し、標準の生物分析プロトコルを使用して、血漿および脳のサンプルを処理し、分析した。3匹のマウスを以下の時間点で屠殺した:15分、1時間および4時間。血液を、血漿採取のためにリチウムヘパリンチューブに集めた。脳サンプルを、FastPrep−24組織ホモジナイザーを使用して、抽出前に均質化した。血漿および脳のホモジネートを、内部標準(IS)としてベラパミルを含有しているアセトニトリルを用いてタンパク質沈殿によって抽出した。10分間ボルテックスした後に、サンプルを、96ウェルのフィルタプレートに移し、遠心分離機を使用して濾過した。濾液をLC/MS/MSによって分析した。化合物を、較正曲線を使用してソフトウェアで定量化した。化合物1の血漿(■)および脳(●)の濃度が示される。(図10を参照)動物の体重および臨床観察は、研究の全体にわたって正常に見えた。
化合物1は、神経炎症の実験的な自己免疫性脳脊髄炎の動物モデルにおいて動物の回復を増強した。実験的な自己免疫性脳脊髄炎を、中枢神経系炎症、神経単の脱髄、軸索損傷、および神経変性により麻痺を引き起こす、ミエリン由来抗原に対して特異的なCD4+T細胞によって媒介する。C57/Bl6マウスに対して、完全なフロイントアジュバント中のミエリンオリゴデンドロサイト糖タンパク質MOG35−55での免疫化によって神経炎症を誘発し、その後、リン酸緩衝生理食塩水中の百日咳毒素を投与した。化合物1を、20gのプロピレングリコール、20gのポリエチレングリコール400、および1gのTween 80の混合物2.3046mL中に溶解し、その後、撹拌しながら0.9%の生理食塩水3.7854mL中に溶解することによって、インビボでの投与のために5mg/kgの化合物1を調製した。
Claims (15)
- 式(III)の構造を有する化合物、あるいはその薬学的に許容可能な塩、または溶媒和物であって、
R1はそれぞれ独立して、H、F、Cl、あるいはBrであり、
R8は、F、Cl、Br、C1−C6アルキル、C1−C6フルオロアルキル、C1−C6シクロアルキル、あるいはC1−C6ヒドロキシアルキルであり、
R9は、F、Cl、Br、C1−C6アルキル、C1−C6ヒドロキシアルキル、−OH、または−OR11であり、
R10は、H、F、Cl、Br、C1−C6アルキル、C1−C6フルオロアルキル、あるいは、C1−C6シクロアルキルであり、
R11はC1−C6アルキルであり、
nは0、1、2、または3であり、および、
mは0または1である、化合物、あるいはその薬学的に許容可能な塩または溶媒和物。 - R1はそれぞれ独立して、HまたはClである、請求項1に記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- R1はそれぞれHである、請求項1または2に記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- R1はそれぞれClである、請求項1または2に記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- R8は、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、tert−ブチル、ペンチル、ネオペンチル、ヘキシル、シクロプロピル、またはシクロブチルである、請求項1−4のいずれか1つに記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- R8は、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、またはtert−ブチルである、請求項1−5のいずれか1つに記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- R9は、F、Cl、Br、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、tert−ブチル、ペンチル、ネオペンチル、ヘキシル、C1−C6ヒドロキシアルキル、−OH、メトキシ、エトキシ、プロポキシ、または、ブトキシである、請求項1−6のいずれか1つに記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- R9は−OHである、請求項1−7のいずれか1つに記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- R10は、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、または第三級ブチルである、請求項1−8のいずれか1つに記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- nは2または3であり;及び
mは1である、請求項1−9のいずれか1つに記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。 - 化合物は以下である、請求項1に記載の化合物、あるいはその薬学的に許容可能な塩または溶媒和物。
- 請求項1−11のいずれか1つの化合物、あるいはその薬学的に許容可能な塩または溶媒和物、および、少なくとも1つの薬学的に許容可能な賦形剤を含む医薬組成物。
- 治療による処置方法における使用のための;あるいは、Ca2+放出活性化Ca2+(CRAC)チャネル関連疾患または障害を処置する方法における使用のための、請求項12の組成物。
- Ca2+放出活性化Ca2+(CRAC)チャネル関連疾患または障害は、炎症、癌または他の増殖性疾患、肝臓の疾患または障害、腎臓の疾患または障害、あるいは炎症性の肺障害に関与する免疫系関連の疾患または障害である、請求項13に記載の組成物。
- Ca2+放出活性化Ca2+(CRAC)チャネル関連疾患または障害は、炎症、糸球体腎炎、ブドウ膜炎、肝臓の疾患または障害、腎臓の疾患または障害、炎症性の肺障害、慢性閉塞性肺疾患、関節リウマチ、炎症性腸疾患、血管炎、皮膚炎、変形性関節症、炎症性の筋肉疾患、アレルギー性鼻炎、膣炎、間質性膀胱炎、強皮症、骨粗鬆症、湿疹、同種移植または異種移植、移植片拒絶反応、移植片対宿主病、紅斑性狼瘡、肺線維症、皮膚筋炎、甲状腺炎、重症筋無力症、自己免疫性溶血性貧血、嚢胞性線維症、慢性の再発性肝炎、原発性胆汁性肝硬変、アレルギー性結膜炎、肝炎、アトピー性皮膚炎、喘息、シェーグレン症候群、移植臓器拒絶、多発性硬化症、ギラン・バレー症候群、自己免疫性ブドウ膜炎、自己免疫性溶血性貧血、悪性貧血、自己免疫性血小板減少、側頭動脈炎、抗リン脂質抗体症候群、ヴェーゲナー肉芽腫症、ベーチェット病のような血管炎、乾癬、疱疹状皮膚炎、尋常性天疱瘡、白斑、クローン病、大腸炎、潰瘍性大腸炎、原発性胆汁性肝硬変、自己免疫性肝炎、1型または免疫媒介性の真性糖尿病、グレーブス病、橋本甲状腺炎、自己免疫性卵巣炎と精巣炎、副腎の自己免疫障害、全身性エリテマトーデス、多発性筋炎、皮膚筋炎、強直性脊椎炎、移植拒絶反応、皮膚移植片拒絶反応、関節炎、骨吸収の増加に関連する骨疾患、回腸炎、バレット症候群、成人呼吸窮迫症候群、慢性閉塞性気道疾患;角膜変性、トラコーマ、オンコセルカ症、交感性眼炎、眼内炎;歯肉炎、歯周炎;結核;ハンセン病;尿毒症の合併症、ネフローゼ;硬化性皮膚炎、乾癬、神経系の慢性脱髄症、エイズ関連の神経変性、アルツハイマー病、感染性髄膜炎、脳脊髄炎、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、ウイルスまたは自己免疫性の脳炎;自己免疫障害、免疫複合体血管炎、全身性紅斑性およびエリテマトーデス;全身性エリテマトーデス(SLE);心筋症、虚血性心疾患高コレステロール血症、アテローム性動脈硬化症、子癇前症;慢性肝不全、脳と脊髄の損傷、あるいは癌である、請求項13に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103033P | 2015-01-13 | 2015-01-13 | |
US62/103,033 | 2015-01-13 | ||
PCT/US2016/012909 WO2016115054A2 (en) | 2015-01-13 | 2016-01-11 | Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018502083A JP2018502083A (ja) | 2018-01-25 |
JP2018502083A5 JP2018502083A5 (ja) | 2019-02-14 |
JP6764866B2 true JP6764866B2 (ja) | 2020-10-07 |
Family
ID=56406559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017533635A Expired - Fee Related JP6764866B2 (ja) | 2015-01-13 | 2016-01-11 | Ca2+放出活性化Ca2+(CRAC)チャネルのモジュレーターおよびその薬学的使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10213412B2 (ja) |
EP (1) | EP3245189B1 (ja) |
JP (1) | JP6764866B2 (ja) |
CN (1) | CN107207431B (ja) |
AU (1) | AU2016207014B2 (ja) |
CA (1) | CA2969814C (ja) |
ES (1) | ES2825798T3 (ja) |
HK (1) | HK1245797A1 (ja) |
MX (1) | MX2017009164A (ja) |
WO (1) | WO2016115054A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207431B (zh) | 2015-01-13 | 2021-02-09 | 维夫雷昂生物科学有限责任公司 | Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 |
EA202090681A1 (ru) * | 2017-10-17 | 2020-07-21 | Ризен Фармасьютикалз Са | Модуляторы каналов crac для лечения рака пищевода |
KR20200079256A (ko) * | 2017-10-30 | 2020-07-02 | 리젠 파마슈티컬스 소시에떼 아노님 | 혈액암 및 고형암을 치료하기 위한 칼슘 방출-활성화된 칼슘 채널 조절제 |
AU2019340601A1 (en) | 2018-09-14 | 2021-05-13 | Rhizen Pharmaceuticals A G | Compositions comprising a CRAC inhibitor and a corticosteroid and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4644009A (en) | 1984-10-29 | 1987-02-17 | Usv Pharmaceutical Corporation | Aryl-alkyl heterocyclic compounds |
US5041442A (en) * | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
CA2131024A1 (en) * | 1992-03-06 | 1993-09-16 | Arsalan Kharazmi | Treatment and prophylaxis of diseases caused by parasites, or bacteria |
DE69529056T2 (de) * | 1994-01-19 | 2003-11-13 | Sankyo Co | Pyrrolopyridazin-derivate |
JP3143571B2 (ja) * | 1994-01-19 | 2001-03-07 | 三共株式会社 | ピロロピリダジン誘導体 |
JP2000256358A (ja) * | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
US7709518B2 (en) * | 2004-09-21 | 2010-05-04 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
CA2612661A1 (en) * | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
TW201130488A (en) * | 2010-02-03 | 2011-09-16 | Daiichi Sankyo Co Ltd | Pyrrole compound |
PT2723710T (pt) * | 2011-06-27 | 2016-11-14 | Newron Pharm Spa | Derivados fluorados de arilalquilaminocarboxamida |
US9504680B2 (en) * | 2013-06-17 | 2016-11-29 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
CN107207431B (zh) | 2015-01-13 | 2021-02-09 | 维夫雷昂生物科学有限责任公司 | Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 |
-
2016
- 2016-01-11 CN CN201680005731.2A patent/CN107207431B/zh active Active
- 2016-01-11 CA CA2969814A patent/CA2969814C/en active Active
- 2016-01-11 ES ES16737683T patent/ES2825798T3/es active Active
- 2016-01-11 EP EP16737683.9A patent/EP3245189B1/en active Active
- 2016-01-11 JP JP2017533635A patent/JP6764866B2/ja not_active Expired - Fee Related
- 2016-01-11 AU AU2016207014A patent/AU2016207014B2/en not_active Ceased
- 2016-01-11 US US15/539,088 patent/US10213412B2/en active Active
- 2016-01-11 WO PCT/US2016/012909 patent/WO2016115054A2/en active Application Filing
- 2016-01-11 MX MX2017009164A patent/MX2017009164A/es unknown
-
2018
- 2018-04-27 HK HK18105487.9A patent/HK1245797A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3245189A4 (en) | 2018-07-18 |
US10213412B2 (en) | 2019-02-26 |
CA2969814A1 (en) | 2016-07-21 |
AU2016207014B2 (en) | 2020-07-16 |
WO2016115054A2 (en) | 2016-07-21 |
CN107207431B (zh) | 2021-02-09 |
CN107207431A (zh) | 2017-09-26 |
ES2825798T3 (es) | 2021-05-17 |
JP2018502083A (ja) | 2018-01-25 |
US20180263960A1 (en) | 2018-09-20 |
WO2016115054A3 (en) | 2016-09-01 |
CA2969814C (en) | 2023-06-13 |
EP3245189B1 (en) | 2020-07-22 |
EP3245189A2 (en) | 2017-11-22 |
MX2017009164A (es) | 2018-03-06 |
AU2016207014A1 (en) | 2017-07-06 |
HK1245797A1 (zh) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108884126B (zh) | 用于治疗眼睛病症或疾病的化合物 | |
KR102181914B1 (ko) | T-세포 반응을 조절할 수 있는 헤테로사이클 및 그의 사용 방법 | |
US11530219B2 (en) | Ligands to cereblon (CRBN) | |
TWI710552B (zh) | 作為神經元組織胺受體-3拮抗劑之化合物及其用途 | |
JP6764866B2 (ja) | Ca2+放出活性化Ca2+(CRAC)チャネルのモジュレーターおよびその薬学的使用 | |
JP4897683B2 (ja) | チエノピリジノン化合物及び治療方法 | |
WO2017180769A1 (en) | Small molecules for immunogenic treatment of cancer | |
US9637484B2 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
CN108349964A (zh) | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 | |
JP2016537389A (ja) | オートタキシン阻害剤化合物 | |
CN105121429A (zh) | 补体途径调节剂和其用途 | |
BR112016018341B1 (pt) | Composto de triazina, seu uso para propósitos médicos, composição farmacêutica, inibidor de mpges1 e agente profilático ou terapêutico | |
JP2010523725A (ja) | 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン | |
CN115025086A (zh) | 双环杂芳基衍生物及其制备与用途 | |
US11618752B2 (en) | Compositions, uses and methods for making them | |
TW201737943A (zh) | 使用fasn抑制劑之方法 | |
JP2021519316A (ja) | Tlr2シグナル伝達の調節剤としての化合物 | |
WO2017190708A1 (zh) | 吡唑‐三嗪类衍生物、其制备方法、药物组合物和用途 | |
WO2022125614A1 (en) | Phosphonates as inhibitors of enpp1 and cdnp | |
JP2023512413A (ja) | ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 | |
CA3138780A1 (en) | Method for treating cough by using diaminopyrimidine compound | |
US20230241025A1 (en) | Antiviral use of fabp4 modulating compounds | |
US20230255933A1 (en) | Antiviral use of fabp4 modulating compounds | |
WO2024050431A2 (en) | Tapinarof and analogs thereof for use in treating ahr mediated diseases | |
US20230159439A1 (en) | Arylamides and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181227 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200717 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200824 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200914 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6764866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |